- Neurosarcoidosis treatment, involving immunosuppressive therapies, corticosteroids, and biologics, is an essential focus area in the management of chronic inflammatory neurological disorders, gaining clinical importance due to its potentially debilitating effects on the central and peripheral nervous systems
- The rising incidence of sarcoidosis with neurological involvement, combined with greater physician awareness and improved diagnostic imaging, is fueling the demand for effective and targeted treatment protocols
- North America led the neurosarcoidosis treatment market with the largest revenue share of 41.1% in 2024, supported by advanced healthcare infrastructure, higher rates of diagnosis, and the presence of key pharmaceutical and biotech companies investing in rare disease drug development
- The Asia-Pacific region is projected to witness the fastest growth during the forecast period, driven by improved healthcare access, rising disease awareness, and increased clinical research initiatives across emerging economies
- Drugs segment dominated the neurosarcoidosis treatment market with a market share of 68% in 2024, driven by its effectiveness in managing inflammation and symptoms through corticosteroids, immunosuppressants, and emerging biologic therapies
